Biocon, Pfizer scrap insulin deal

March 13, 2012 12:45 pm | Updated 09:44 pm IST - New Delhi

Founder chairperson and Managing Director Biocon limted Dr. Kiran Mazumdar Shaw. File photo

Founder chairperson and Managing Director Biocon limted Dr. Kiran Mazumdar Shaw. File photo

Biocon and Pfizer have decided to terminate their pact to commercialise biosimilar versions of insulin and insulin analog products.

A joint statement issued by them said the two firms had decided ‘to move forward independently' to focus on their ‘individual priorities' pertaining to their biosimilar business.

Following this, the rights licensed to Pfizer by Biocon would revert to the Indian company. Biocon Chairman and Managing Director Kiran Mazumdar Shaw said Biocon would pursue its own commercial strategy and access other markets ‘through new alliances'. The two companies entered into the agreement in October, 2010, which resulted in the U.S. multi-national making an ‘upfront investment' of $200 million.

Biocon was also to receive an additional $150 million on fulfilling drug ‘development and regulatory milestones.' In addition, Pfizer was to make payments to Biocon for selling the company's biosimilars across global markets.

In September, 2011, Biocon invested about $160 million in a new facility in Malaysia to manufacture drugs to treat diabetes that were being commercialised by Pfizer. Both said they were “committed to ensuring continuity of patient care and will work together to effect a seamless transition.”

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.